ascopubs.org

Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing ...

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...
Labroots

Accelerating insights into changes in binding affinity of biomolecular charge variants using a simple icIEF fractionation and SPR workflow

Charge heterogeneity in monoclonal antibodies can negatively impact binding affinity and potency, so it is critical to ensure that individual charge variants of biotherapeutic molecules are thoroughly ...
News Medical

Assessing small molecule kinetics and affinity through SPR screening

Fragment-based drug discovery (FBDD) has gained widespread recognition as a valuable approach in the search for lead drug candidates in drug discovery programs. It is utilized in conjunction with ...
GEN

SPR Expands the Knowledge of Proteins

Surface plasmon resonance (SPR) technology is expanding strategies for studying and analyzing binding kinetics, offering real-time, label-free analysis. Researchers at the “Developments in Protein ...
Nasdaq

Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442

SEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ...
Labroots

Challenging the 'Art' of SPR with Live Q&A

Surface plasmon resonance is a real-time and label-free technique that offers low sample consumption and high throughput when compared to other biophysical techniques and has been widely adopted in ...